Structure Therapeutics Inc. (GPCR) NASDAQ
Currency In USD
AD
- General
- Statistics
- Historical Data
- Profile
- Financials
AD
Currency In USD
| Previous Close | 50.52 |
| Open | 50.61 |
| Day High | 50.96 |
| Day Low | 49.02 |
| 52-Week High | 94.9 |
| 52-Week Low | 18.26 |
| Volume | 592,478 |
| Average Volume | 712,735 |
| Market Cap | 2.83B |
| PE | -31.27 |
| EPS | -1.57 |
| Moving Average 50 Days | 50.07 |
| Moving Average 200 Days | 53.7 |
| Change | -1.43 |
Structure Therapeutics Announces Initiation of Phase 1 Clinical Study of Oral Small Molecule Amylin Receptor Agonist ACCG-2671 for the Treatment of Obesity
GlobeNewswire Inc.
Dec 17, 2025 1:30 PM GMT
SAN FRANCISCO, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today
Structure Therapeutics Announces Closing of Upsized $747.5 Million Public Offering of ADSs and Pre-Funded Warrants and Full Exercise of the Underwriters’ Option to Purchase Additional ADSs
GlobeNewswire Inc.
Dec 11, 2025 9:01 PM GMT
SAN FRANCISCO, Dec. 11, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today
Structure Therapeutics Announces Pricing of Upsized $650 Million Public Offering of ADSs and Pre-Funded Warrants
GlobeNewswire Inc.
Dec 10, 2025 4:15 AM GMT
SAN FRANCISCO, Dec. 09, 2025 (GLOBE NEWSWIRE) -- Structure Therapeutics Inc. (NASDAQ: GPCR), a clinical-stage global biopharmaceutical company developing novel oral small molecule therapeutics for metabolic diseases, with a focus on obesity, today